Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties

Rakesh, David Bruhn, Dora B. Madhura, Marcus Maddox, Robin B. Lee, Ashit Trivedi, Lei Yang, Michael S. Scherman, Janet C. Gilliland, Veronica Gruppo, Michael R. McNeil, Anne J. Lenaerts, Bernd Meibohm, Richard E. Lee

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

A series of tetracyclic nitrofuran isoxazoline anti-tuberculosis agents was designed and synthesized to improve the pharmacokinetic properties of an initial lead compound, which had potent anti-tuberculosis activity but suffered from poor solubility, high protein binding and rapid metabolism. In this study, structural modifications were carried on the outer phenyl and piperidine rings to introduce solubilizing and metabolically blocking functional groups. The compounds generated were evaluated for their in vitro antitubercular activity, bacterial spectrum of activity, solubility, permeability, microsomal stability and protein binding. Pharmacokinetic profiles for the most promising candidates were then determined. Compounds with phenyl morpholine and pyridyl morpholine outer rings were found to be the most potent anti-tuberculosis agents in the series. These compounds retained a narrow antibacterial spectrum of activity, with weak anti-Gram positive and no Gram negative activity, as well as good activity against non-replicating Mycobacterium tuberculosis in a low oxygen model. Overall, the addition of solubilizing and metabolically blocked outer rings did improve solubility and decrease protein binding as designed. However, the metabolic stability for compounds in this series was generally lower than desired. The best three compounds selected for in vivo pharmacokinetic testing all showed high oral bioavailability, with one notable compound showing a significantly longer half-life and good tolerability supporting its further advancement.

Original languageEnglish (US)
Pages (from-to)6063-6072
Number of pages10
JournalBioorganic and Medicinal Chemistry
Volume20
Issue number20
DOIs
StatePublished - Oct 15 2012

Fingerprint

Nitrofurans
Pharmacokinetics
Protein Binding
Solubility
Tuberculosis
Lead compounds
Mycobacterium tuberculosis
Metabolism
Functional groups
Biological Availability
Half-Life
Permeability
Oxygen
Testing
morpholine

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Rakesh, Bruhn, D., Madhura, D. B., Maddox, M., Lee, R. B., Trivedi, A., ... Lee, R. E. (2012). Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. Bioorganic and Medicinal Chemistry, 20(20), 6063-6072. https://doi.org/10.1016/j.bmc.2012.08.023

Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. / Rakesh; Bruhn, David; Madhura, Dora B.; Maddox, Marcus; Lee, Robin B.; Trivedi, Ashit; Yang, Lei; Scherman, Michael S.; Gilliland, Janet C.; Gruppo, Veronica; McNeil, Michael R.; Lenaerts, Anne J.; Meibohm, Bernd; Lee, Richard E.

In: Bioorganic and Medicinal Chemistry, Vol. 20, No. 20, 15.10.2012, p. 6063-6072.

Research output: Contribution to journalArticle

Rakesh, Bruhn, D, Madhura, DB, Maddox, M, Lee, RB, Trivedi, A, Yang, L, Scherman, MS, Gilliland, JC, Gruppo, V, McNeil, MR, Lenaerts, AJ, Meibohm, B & Lee, RE 2012, 'Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties', Bioorganic and Medicinal Chemistry, vol. 20, no. 20, pp. 6063-6072. https://doi.org/10.1016/j.bmc.2012.08.023
Rakesh ; Bruhn, David ; Madhura, Dora B. ; Maddox, Marcus ; Lee, Robin B. ; Trivedi, Ashit ; Yang, Lei ; Scherman, Michael S. ; Gilliland, Janet C. ; Gruppo, Veronica ; McNeil, Michael R. ; Lenaerts, Anne J. ; Meibohm, Bernd ; Lee, Richard E. / Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. In: Bioorganic and Medicinal Chemistry. 2012 ; Vol. 20, No. 20. pp. 6063-6072.
@article{8bd26d17df614267a9c12cbd078fd652,
title = "Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties",
abstract = "A series of tetracyclic nitrofuran isoxazoline anti-tuberculosis agents was designed and synthesized to improve the pharmacokinetic properties of an initial lead compound, which had potent anti-tuberculosis activity but suffered from poor solubility, high protein binding and rapid metabolism. In this study, structural modifications were carried on the outer phenyl and piperidine rings to introduce solubilizing and metabolically blocking functional groups. The compounds generated were evaluated for their in vitro antitubercular activity, bacterial spectrum of activity, solubility, permeability, microsomal stability and protein binding. Pharmacokinetic profiles for the most promising candidates were then determined. Compounds with phenyl morpholine and pyridyl morpholine outer rings were found to be the most potent anti-tuberculosis agents in the series. These compounds retained a narrow antibacterial spectrum of activity, with weak anti-Gram positive and no Gram negative activity, as well as good activity against non-replicating Mycobacterium tuberculosis in a low oxygen model. Overall, the addition of solubilizing and metabolically blocked outer rings did improve solubility and decrease protein binding as designed. However, the metabolic stability for compounds in this series was generally lower than desired. The best three compounds selected for in vivo pharmacokinetic testing all showed high oral bioavailability, with one notable compound showing a significantly longer half-life and good tolerability supporting its further advancement.",
author = "Rakesh and David Bruhn and Madhura, {Dora B.} and Marcus Maddox and Lee, {Robin B.} and Ashit Trivedi and Lei Yang and Scherman, {Michael S.} and Gilliland, {Janet C.} and Veronica Gruppo and McNeil, {Michael R.} and Lenaerts, {Anne J.} and Bernd Meibohm and Lee, {Richard E.}",
year = "2012",
month = "10",
day = "15",
doi = "10.1016/j.bmc.2012.08.023",
language = "English (US)",
volume = "20",
pages = "6063--6072",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "20",

}

TY - JOUR

T1 - Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties

AU - Rakesh,

AU - Bruhn, David

AU - Madhura, Dora B.

AU - Maddox, Marcus

AU - Lee, Robin B.

AU - Trivedi, Ashit

AU - Yang, Lei

AU - Scherman, Michael S.

AU - Gilliland, Janet C.

AU - Gruppo, Veronica

AU - McNeil, Michael R.

AU - Lenaerts, Anne J.

AU - Meibohm, Bernd

AU - Lee, Richard E.

PY - 2012/10/15

Y1 - 2012/10/15

N2 - A series of tetracyclic nitrofuran isoxazoline anti-tuberculosis agents was designed and synthesized to improve the pharmacokinetic properties of an initial lead compound, which had potent anti-tuberculosis activity but suffered from poor solubility, high protein binding and rapid metabolism. In this study, structural modifications were carried on the outer phenyl and piperidine rings to introduce solubilizing and metabolically blocking functional groups. The compounds generated were evaluated for their in vitro antitubercular activity, bacterial spectrum of activity, solubility, permeability, microsomal stability and protein binding. Pharmacokinetic profiles for the most promising candidates were then determined. Compounds with phenyl morpholine and pyridyl morpholine outer rings were found to be the most potent anti-tuberculosis agents in the series. These compounds retained a narrow antibacterial spectrum of activity, with weak anti-Gram positive and no Gram negative activity, as well as good activity against non-replicating Mycobacterium tuberculosis in a low oxygen model. Overall, the addition of solubilizing and metabolically blocked outer rings did improve solubility and decrease protein binding as designed. However, the metabolic stability for compounds in this series was generally lower than desired. The best three compounds selected for in vivo pharmacokinetic testing all showed high oral bioavailability, with one notable compound showing a significantly longer half-life and good tolerability supporting its further advancement.

AB - A series of tetracyclic nitrofuran isoxazoline anti-tuberculosis agents was designed and synthesized to improve the pharmacokinetic properties of an initial lead compound, which had potent anti-tuberculosis activity but suffered from poor solubility, high protein binding and rapid metabolism. In this study, structural modifications were carried on the outer phenyl and piperidine rings to introduce solubilizing and metabolically blocking functional groups. The compounds generated were evaluated for their in vitro antitubercular activity, bacterial spectrum of activity, solubility, permeability, microsomal stability and protein binding. Pharmacokinetic profiles for the most promising candidates were then determined. Compounds with phenyl morpholine and pyridyl morpholine outer rings were found to be the most potent anti-tuberculosis agents in the series. These compounds retained a narrow antibacterial spectrum of activity, with weak anti-Gram positive and no Gram negative activity, as well as good activity against non-replicating Mycobacterium tuberculosis in a low oxygen model. Overall, the addition of solubilizing and metabolically blocked outer rings did improve solubility and decrease protein binding as designed. However, the metabolic stability for compounds in this series was generally lower than desired. The best three compounds selected for in vivo pharmacokinetic testing all showed high oral bioavailability, with one notable compound showing a significantly longer half-life and good tolerability supporting its further advancement.

UR - http://www.scopus.com/inward/record.url?scp=84866889588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866889588&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2012.08.023

DO - 10.1016/j.bmc.2012.08.023

M3 - Article

VL - 20

SP - 6063

EP - 6072

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 20

ER -